Results 161 to 170 of about 5,662,994 (304)

Editorial

NORDEUROPAforum - Zeitschrift für Kulturstudien, 2013
Dose, Inken, Volquardsen, Ebbe
doaj   +1 more source

Dosimetric comparison of sequential planning (SP) versus bias dose planning (BDP) in volumetric modulated arc therapy (VMAT)-based breast radiotherapy boost. [PDF]

J Appl Clin Med Phys
Mani T, Duraikannu P, Ramalingam C, Kondeti AK.   +3 more
europepmc   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Revisiting the Chondrotoxicity of Intra-Articular Triamcinolone Acetonide in Osteoarthritis: Dose Dependence and Experimental Model Heterogeneity [Letter]. [PDF]

J Pain Res
Liu Q, Du H.
europepmc   +1 more source

Thermal dose and thermal isoeffect dose [PDF]

International Journal of Hyperthermia, 1989
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Enoxaparin Dosing and Target anti-Factor Xa Achievement in Infants by Postmenstrual Age. [PDF]

J Pediatr Pharmacol Ther
Perez D, Mathew K.
europepmc   +1 more source

[Equivalent dose or dose equivalence?].

Arhiv za higijenu rada i toksikologiju, 1994
In the Croatian language the terms denoting certain physical quantities in the field of radiation protection dosimetry lack precision. Consequently, either the English expressions or mathematical formulas are used instead. The situation is even worse as only a limited number of textbooks, reference books and professional papers are available in the ...
openaire   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source